Field Trip Health & Wellness Ltd. (FTHWF) has received an Initial Order for creditor protection from the Ontario Superior Court under the Companies’ Creditors Arrangement Act (CCAA). This decision follows a comprehensive review of the company’s financial situation by its Board of Directors. The CCAA process aims to facilitate a sale and investment solicitation to ensure the company's survival. A significant corporate restructuring includes staff reductions, the resignation of CEO Ronan Levy, and the appointment of Keith Merker as Chief Restructuring Officer. Trading of FTHWF shares has been suspended, and the company has been authorized to incur no further expenses related to disclosure obligations during this period.
Field Trip Health & Wellness Ltd. (TSX-V: FTHW) announced the closure of five Health Centres in Chicago, Washington DC, Seattle, San Diego, and Fredericton, effective around April 15, 2023. This decision aims to reduce expenditures and conserve capital. Clients are being notified and provided with information on alternative care and accessing their medical records. The Independent Committee continues to explore strategic options, including further cost reductions and potential restructuring. The company emphasizes its commitment to the psychedelic therapy community while navigating financial challenges.
Field Trip Health & Wellness reported fiscal third quarter 2023 results, highlighting its ongoing strategic review in response to unfavorable capital market conditions and regulatory changes affecting its Freedom Program. The firm generated $1.62 million in patient services revenue for Q3 2023, up from $1.36 million in Q3 2022, totaling $5.29 million for the nine-month period, compared to $3.14 million in the previous year. Operating expenses were $8.18 million for Q3, down from $9.67 million year-over-year. The net loss improved to $(6.93 million) from $(8.84 million). As of December 31, 2022, cash and equivalents stood at $6.72 million.
Field Trip Health & Wellness Ltd. (OTCQB: FTHWF) will release its financial results for Q3 fiscal 2023, ending December 31, 2022, on February 28, 2023. In response to challenging capital market conditions, the Board has formed an Independent Committee to explore strategic options. This includes reviewing operations and possibly restructuring, cost reductions, subleasing, or closing clinic locations. The pause of the hybrid Freedom Program due to regulatory changes is also highlighted as a significant concern. The Company aims to provide updated recommendations post-review.
Field Trip Health & Wellness Ltd. (FTHW) has commenced trading on the OTCQB under the symbol FTHWF as of February 2, 2023. This strategic move aims to enhance visibility and liquidity for U.S. investors, according to CEO Ronan Levy. The Company also announced that it is reevaluating its Freedom by Field Trip program due to the U.S. government's intention to end the Public Health Emergency related to COVID-19, resulting in the halt of new client enrollments. Field Trip is recognized for its innovative psychedelic therapies addressing mental health challenges.